Collaboration and Licensing Revenue - Additional Information (Details)	1 Months Ended						12 Months Ended						24 Months Ended
	Jul. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Feb. 29, 2020 USD ($)	Dec. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Oct. 31, 2012 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) product	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2020 USD ($)
Collaboration Agreements [Line Items]
Deferred revenue							$ 27,465,000							$ 25,823,000
Required notice period for voluntary termination of collaborative agreement							90 days
Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible									20.00%
License agreement, percentage of operating profits to be received									20.00%
License agreement, annual fee									$ 100,000
License agreement, reimbursement of historical costs								$ 1,000,000
Milestone payments required upon successful achievement, aggregated									210,000,000
License agreement, royalty due, aggregated									$ 100,000,000
License agreement, percentage of sublicensing income									20.00%
Transition period during which costs will be reimbursed									1 year
License agreement, termination, period following triggering event									12 years
Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue							$ 23,023,000							$ 23,420,000
Maximum | Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product									$ 52,500,000
License agreement, number of exclusively licensed products | product									4
Alaunos Therapeutics, Inc. | Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible									80.00%
License agreement, percentage of operating profits to be received									80.00%
License agreement, royalty due, aggregated									$ 50,000,000
Alaunos Therapeutics, Inc. | Collaboration and licensing agreements | Transition services
Collaboration Agreements [Line Items]
Deferred revenue									$ 1,855,000
Oragenics, Inc. | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value of convertible promissory note										$ 5,000,000
Revenue recognized from previously deferred balances	$ 2,823,000
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value					$ 25,000,000						$ 25,000,000
Required notice period for voluntary termination of collaborative agreement					90 days
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value				$ 18,000,000						$ 18,000,000
Required notice period for voluntary termination of collaborative agreement				90 days
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue															$ 6,993,000
Collaborative agreement, consideration received, value													$ 11,000,000
Castle Creek Biosciences, Inc. | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenue recognized from previously deferred balances			$ 10,000,000
Collaborative agreement, consideration received, value						$ 7,576,000						$ 7,612,000
Collaborative agreement, consideration received, cash								$ 3,750,000
Royalty rate as a percentage of net sales, tier 1		7.00%
Level of net sales at which royalty rate changes to tier 2		$ 25,000,000
Royalty rate as a percentage of net sales, tier 2		14.00%